A panel of experts on Friday voted in favor of bringing what could be the first-ever drug approved specifically for postpartum depression to market. But should it get the expected green light from the FDA next month, how widely will the treatment, which requires a continuous, 60-hour intravenous infusion that a professional will have to monitor, be used?
By a 17 to 1 vote, with one abstention, the panel agreed that the benefits of the drug outweigh its risks for treating postpartum depression, or PPD-as long as patients are monitored in a healthcare facility and the treatment is administered under a… Read more »
UNDERWRITERS AND PARTNERS